Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled date : 2021 - 12 - 22 save search
Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
Published: 2021-12-22 (Crawled : 14:00) - biospace.com/
SGHT | $5.64 5.03% 4.79% 130K
|
|
| O: 0.48%
H: 1.62%
C: -3.82%
tearcare dry eye treatment fda clearance eye eye disease disease
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
alzheimer treatment application disease alzheimer’s alzheimer's disease alzheimer's
Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
Published: 2021-12-22 (Crawled : 12:30) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: -2.93%
H: 2.98%
C: 1.92%
disease infectious disease
Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design
Published: 2021-12-22 (Crawled : 12:30) - biospace.com/
TSHA | $2.525 2.64% 2.57% 1.5M
|
Health Technology
|
| O: -0.59%
H: 1.04%
C: -2.01%
disease gene therapies positive gene therapy designation
UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease
Published: 2021-12-22 (Crawled : 12:30) - globenewswire.com
MREO | $2.79 0.0% 790K
|
Health Technology
|
| O: 0.61%
H: 0.6%
C: -3.01%
mph966 covid-19 respiratory phase 1b trial covid disease phase 1 positive results topline phase 2b alvelestat
XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease
Published: 2021-12-21 (Crawled : 01:00) - globenewswire.com
XRTX | News | $2.88 -2.41% 8.3K
|
Mining, Quarrying, and Oil and ...
|
| O: 3.09%
H: 2.99%
C: -2.0%
patent therapeutics disease kidney
Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases
Published: 2021-12-22 (Crawled : 01:00) - globenewswire.com
ALLK | $1.055 -0.47% -0.47% 270K
|
Health Technology
|
| O: -87.46%
H: 2.55%
C: -19.19%
phase 2 phase 2/3 gastrointestinal disease test topline phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.